arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MEDICINOVA INC

MNOV
$1.45 ▼ -0.01 (-0.68%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
78 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

MEDICINOVA INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $71.4M
Dividend Yield —
Revenue Growth 240.6%
Op. Margin None
ROIC -5.4% ↗
FCF / Share $-0.04 ↗
Trailing P/E —
Price / Book 1.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

78-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$458.44K
↑ +240.6% —
Net Income Profit after all expenses
$-2.59M
↑ +9.7% —
Operating Margin Operating profit as % of sales
-114.7%
↓ -2176.4% —
FCF / Share Free cash flow per share
$-0.04
↑ +44.8% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
24
Cash Quality ↓
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 26 years · 78 quarters